Indeed, there is evidence demonstrating significant regional variation and lower PSA testing rates in areas of greater deprivation.30 Although evidence exists that higher rates of opportunistic PSA testing may reduce diagnosis of metastatic prostate cancer,31 whether variation in PSA testing leads to differences in prostate cancer mortality is unclear. The gene discussed is KLK3; the disease is Familial prostate cancer.